In: Obesity
Stage
No active trials
Next date
None yet
Trials
0 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Pediatric Obesity, Childhood Obesity, Adolescent Obesity, Obesity in Adolescence, Adolescent Overweight, Blood Pressure
- Main trialPhase 4
- “The primary objective of this study is to describe the pharmacokinetic profiles of VI-0521 in obese adolescents.”In the company’s words, NCT02714062 on ClinicalTrials.gov
- Other names
- Qsymia · Phentermine and topiramate · Phentermine/Topiramate
Other drugs for Blood Pressure
- CagriSemaNovo Nordisk · Filed (US)
- HRS-7535Hengrui · Kailera · Filed (China)
- RibupatideHengrui · Kailera · Filed (China)
- RetatrutideEli Lilly · Phase 3
- IN-B00009HK inno.N · Phase 3
- UBT251United Laboratories · Novo Nordisk · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Completed | Oct 2016 | A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents | |
| Phase 4Completed | 16 Apr 2021 | A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity | |
| Phase 4Completed | 11 Apr 2023 | A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026